Madison Square Garden Entertainment: Upgrade To Buy On Better Growth Clarity

Madison Square Garden Entertainment (MSGE) has been upgraded to a Buy rating, reversing a previous Hold, despite a 17% year-over-year revenue decline and an operating loss in Q4 FY25. This upgrade is driven by a significantly improved forward outlook, including robust FY26 event bookings with 80% of The Garden's goal secured, plans for a new high-margin residency to replace Billy Joel's, and strong underlying consumer demand evidenced by high sell-out rates and increased ancillary spending. These factors provide clearer visibility into MSGE's revenue and margin acceleration for FY26 and growth through FY27, shifting the narrative to solid demand recovery and supporting a positive re-rating with a $55 price target based on 15x FY28 adjusted EBITDA.

Analysis

Despite reporting weak 4Q25 results, including a 17% year-over-year revenue decline to $154.1 million and a swing to an adjusted operating loss of $1.3 million from a $13.1 million profit, Madison Square Garden Entertainment's (MSGE) forward-looking outlook has materially improved. The primary driver for this enhanced visibility is the strong booking momentum for fiscal year 2026, which directly addresses previous concerns about a post-Billy Joel residency slowdown. Management has confirmed that MSGE has already secured 80% of its 2026 booking goal at its flagship Garden arena and two-thirds across its theaters, with both metrics pacing ahead of the prior year. This rebound in high-margin concerts, including a record number of shows anticipated for 1Q26, signals a significant inflection in revenue and operating leverage. The outlook is further de-risked by management's disclosure that they are in the late planning stages for a new, multi-date residency for the next calendar year, providing a clear line of sight for growth into FY27. This is complemented by resilient consumer demand, evidenced by high sell-out rates, double-digit growth in per-capita food and beverage spending, and a record-breaking performance of the Christmas Spectacular, which is on track for an even stronger FY26 with 211 scheduled shows.

Key Decisions for Investors

• Investors should consider the weak 4Q25 performance as backward-looking and instead focus on the forward catalysts, as the strong FY26 booking pace and new residency plans suggest a significant positive inflection in revenue and profitability.
• It is crucial to monitor management's execution on securing the new long-term residency and watch for continued strength in ancillary per-capita spending, as these are key pillars supporting the thesis for margin expansion.
• While the outlook is positive, investors should remain cognizant of macroeconomic risks to consumer discretionary spending and the inherent volatility of concert touring schedules, which could impact financial performance.